Search Bar & Filters
Found 67 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating the safety and performance of the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR in patients with coronary artery disease CAD. This observational registry focuses on individuals treated with this specific stent and planned for a short dual antiplatelet therapy DAPT of up to 3 months. The study aims to collect real-world data on clinical outcomes including safety and effectiveness over a 12-month period. Participants in this single-arm registry have undergone percutaneous coronary intervention PCI using the Vivo ISAR stent and will receive standard care short DAPT treatment for no more than 3 months. The study does not affect treatment choices or standard care procedures. After the PCI, eligible patients will be invited to join the registry and followed up at 1 month, 3 months, and 12 months. During the study, researchers will collect baseline medical data and conduct telephonic follow-ups at 30 days, 3 months, and 12 months. These follow-ups will check on medication use, laboratory assessments, adverse events, and any further interventions. The main outcomes measured include ischemic and bleeding events at 12 months, along with secondary outcomes such as mortality, heart attacks, strokes, stent thrombosis, and need for additional vessel treatments. The total participation duration is one year from the PCI procedure.
Actively Recruiting
This trial evaluates the safety and effectiveness of intravenous AOC 1044, also known as delpacibart zotadirsen, in treating boys aged 7 to 16 years with Duchenne Muscular Dystrophy DMD who have gene mutations that can be targeted by exon 44 skipping. The study is a phase 3, randomized, double-blind, placebo-controlled trial with a parallel design. It aims to assess how this treatment impacts physical abilities related to muscle function. Participants will be randomly assigned to receive either AOC 1044 or a placebo through intravenous infusion every 6 weeks for 54 weeks, totaling 9 doses during the double-blind treatment period. After this, all participants have the option to join a 54-week open-label extension, where everyone receives AOC 1044 infusions every 6 weeks for another 9 doses. The study concludes with assessments at week 108 and a safety follow-up at week 114. An independent committee will regularly review safety and efficacy data. During the study, participants will undergo various assessments including tests of muscle strength and function such as time to rise velocity, stair climb, and walkingrunning speed. Quality of life and global impression scores from both patients and caregivers will also be measured. Safety will be closely monitored throughout, with a total participation time of over two years, including the screening, treatment, extension, and follow-up periods.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating MTX325 as a potential disease-modifying treatment for Parkinsons Disease PD in this multi-part Phase 1 trial. The study includes healthy volunteers and patients with mild to moderate and early-stage PD, aiming to assess safety, tolerability, pharmacokinetics, brain biodistribution, and the effects of food on the drug. Parts 1 to 4, involving single and multiple ascending doses in healthy adults including elderly participants, are complete, with Part 5 focusing on multiple doses in PD patients currently ongoing. Participants receive oral capsules of MTX325 at various doses or matching placebo capsules depending on the study part. The trial includes a PET biodistribution study with radiolabeled MTX325 in healthy volunteers. Parts 1 through 4 evaluated single ascending doses, multiple ascending doses, elderly cohorts, and PET biodistribution, while Part 5 involves multiple dosing in PD patients. The study uses a randomized, parallel design without masking. Participants undergo screening including MRI and PET imaging, laboratory testing, ECG, and cognitive assessments before dosing. Safety and tolerability are monitored up to 28 days post-dose. The study involves repeated visits for assessments and dosing, with adherence to scheduled visits and protocols required. Researchers measure adverse events, brain drug distribution, and pharmacokinetics to evaluate MTX325s potential as a PD treatment. The total study duration varies by part, with ongoing follow-up to assess safety and drug effects.
Actively Recruiting
Researchers are evaluating two imaging strategies to improve the treatment of patients with significant calcified coronary artery disease undergoing percutaneous coronary intervention PCI. The study compares a non-invasive coronary CT angiography CCTA-guided calcium modification approach with the current standard intravascular ultrasound IVUS-guided PCI to see if CCTA can enhance procedural efficiency and outcomes while maintaining similar safety. This prospective, multicenter, randomized controlled trial involves 700 patients with flow-limiting stenosis and moderate-to-severe calcification. Participants are randomly assigned to one of two groups one uses CCTA-guided calcium modification, which applies advanced CT imaging to plan and select plaque modification techniques before PCI the other uses IVUS-guided calcium modification following established intravascular ultrasound criteria for plaque preparation and stent optimization. Both groups receive post-procedural IVUS to confirm correct stent implantation. The study measures superiority in final minimal stent area and non-inferiority in 12-month target vessel failure. During the study, participants undergo pre-procedural imaging with either CT or IVUS to assess lesion characteristics. Researchers will evaluate procedure time, radiation exposure, contrast volume, stent area measurements, number of calcium fractures, and clinical safety outcomes including myocardial infarction and stent thrombosis. Patient-reported angina symptoms will also be tracked. The trial continues with follow-up assessments for 12 months to monitor clinical outcomes and safety, with the total participation lasting up to one year post-procedure.
Actively Recruiting
Researchers are investigating NUC-7738, a nucleotide analogue, in patients with advanced solid tumours and lymphoma through a Phase III dose-escalation and expansion study. The study aims to assess the safety, tolerability, and appropriate dosing schedule of NUC-7738 given alone or combined with pembrolizumab. The trial includes patients with various advanced cancers, including cutaneous melanoma and lymphoma, to explore treatment effects and clinical activity of these therapies. Participants receive NUC-7738 intravenously on either a weekly or fortnightly schedule. In combination cohorts, pembrolizumab is administered intravenously every three weeks alongside NUC-7738. Phase I focuses on dose escalation and safety across two dosing schedules, while Phase II involves dose confirmation and expansion in additional patients, including specific cohorts for melanoma and lymphoma. Biopsies are required for most patients to monitor tumour response. During the study, participants undergo regular assessments including tumour size evaluation every 8 weeks, laboratory tests, physical exams, vital signs monitoring, and electrocardiograms up to 22 months. Researchers will track adverse events, dose-limiting toxicities, pharmacokinetics, and clinical responses such as objective response rate and disease control rate. The study continues safety monitoring until 30 days after the last dose, with detailed pharmacokinetic sampling during early cycles.
Actively Recruiting
Researchers are evaluating the effect of LY3457263 compared with placebo on hemoglobin A1c HbA1c levels in adults with type 2 diabetes who have not reached their HbA1c goals despite stable treatment with semaglutide or tirzepatide. This phase 2, double-blind study aims to better understand how LY3457263 impacts blood sugar control in this population. Participants will receive once-weekly subcutaneous injections of either LY3457263 at one of three doses or a placebo, while continuing their stable dose of semaglutide or tirzepatide. The treatment period lasts 24 weeks, during which participants blood sugar and body weight changes will be monitored. The study includes a randomized, parallel-group design comparing these interventions. During the approximately 9-month study, participants will undergo assessments including measurements of HbA1c, fasting serum glucose, and body weight at baseline and week 24. Researchers will monitor safety and treatment effects throughout the study. Participants will have scheduled visits for treatment administration and evaluation, with the primary focus on HbA1c change from baseline at 24 weeks.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating NX-1607, a CBL-B inhibitor, in adults with advanced malignancies that have no effective standard treatments or for whom standard therapies are no longer suitable. This first-in-human Phase 1a1b study aims to assess the safety, tolerability, and anti-cancer activity of NX-1607 in various solid tumors and lymphomas. The study is open-label and includes multiple cancer types such as ovarian, gastric, lung, prostate, breast, and colorectal cancers, among others. The study has two main phases Phase 1a focuses on dose escalation to find safe and tolerable doses of NX-1607 used alone or in combination with paclitaxel. Phase 1a includes evaluation of multiple dosing levels and the effect of food on NX-1607. Phase 1b expands treatment at selected doses in specific cancers, either as monotherapy or combined with paclitaxel. Treatment involves oral NX-1607 and intravenous paclitaxel, with separate cohorts for different tumor types and dosing regimens. Participants will undergo regular assessments including safety monitoring for adverse events, immune-related effects, and dose-limiting toxicities for up to two years. Effectiveness will be measured by tumor response rates and progression-free survival over up to three years. Additional evaluations include blood tests for drug levels and biomarkers, tissue biopsies, and survival tracking. The study requires consent and adherence to protocol restrictions, with ongoing safety and efficacy monitoring throughout the study period.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
1-10 of 67
1